This course will review guidelines for assessment and dental treatment of patients at risk for medication-related osteonecrosis of the jaw (MRONJ) in the setting of cancer, osteoporosis or both. It will also review current evidence regarding routine dental treatment options, including implants, in patients using anti-resorptive medications; and discuss non-surgical and surgical treatment options for ONJ lesions. Prepare to experience an updated review of MRONJ, including current understanding of disease pathogenesis and associated co-morbidities. The risks and benefits of newer anti-resorptive medications and drug protocols will be presented. The latest guidelines for patient assessment, disease prevention and management strategies will be discussed in the clinical setting of cancer patient populations as well as in osteoporosis patients.